Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa in Advanced Renal Cell Carcinoma
NCT00012337Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Efficacy. Started Jan 2001; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00012337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012337.